SynthesisJournal of the American Heart Association2025
Size Matters. Prevalence and Clinical Implications of Left Ventricular Apical Aneurysms in Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis.
Synthesis in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Complication management in hypertrophic cardiomyopathy.Heart failure reviews · 2026Review
- Hypertrophic cardiomyopathy: state of the art on diagnosis and current therapeutic approach.Cardiovascular ultrasound · 2026Review
- Clinical Spectrum and Outcomes in Hypertrophic Cardiomyopathy With Apical Aneurysms: A Large Multicenter International Cohort.JACC. Advances · 2026Article
- 2026 Expert Consensus Recommendations on Hypertrophic Cardiomyopathy: A Report of the Task Force of the Taiwan Society of Cardiology.Acta Cardiologica Sinica · 2026Article
- Large Left Ventricular Aneurysm Caused by Aortic Stenosis and Exacerbated by Prosthesis-Patient Mismatch.JACC. Case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study was to systematically review the recently published literature and determine the prevalence of left ventricular apical aneurysm (LVAA) formation in hypertrophic cardiomyopathy and its association with sudden cardiac death, systemic embolization, and heart failure.
methodsThe protocol was registered with the International Prospective Register of Systematic Reviews (registration number: CRD42023453640). MEDLINE and manual searches for articles published up to August 2023 were performed. Longitudinal, observational cohorts of unselected adult patients with hypertrophic cardiomyopathy were considered. Data were pooled using a random-effects model.
resultsA total of 321 articles fulfilled the search criteria, and 10 retrospective observational studies were selected for the meta-analysis. The pooled prevalence of LVAA was 3% (95% CI, 2%-5%), and 57% of LVAAs were small (<2 cm). Small LVAAs had a lower prevalence of sudden cardiac death end points (4.71% [95% CI, 1.5%-9%) than bigger (≥2 cm) LVAAs (22% [95% CI, 15%-31%), with an odds ratio of 4.65 (95% CI, 2.14-10.10). The prevalence of systemic emboli was also higher in bigger LVAAs (17% [95% CI, 9%-28%) when compared with small LVAA (9% [95% CI, 4%-16%), with an odds ratio of 1.78 (95% CI, 0.53-5.99). Left ventricular thrombi were also more frequently detected in bigger LVAAs (30% [95% CI, 20%-42%) than small LVAAs (2% [95% CI, 0%-6%), with an odds ratio of 10.92 (95% CI, 3.75-31.84). There are scant data on heart failure deaths.
conclusionsThe available data suggest that patients with bigger LVAAs (>2 cm) have the highest risk of poor outcomes and could be preferentially targeted for primary prevention of sudden cardiac death and systemic embolization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.